GlassScriptPhysician profile
Dhaval G Patel
NPI 1831151174
$67,343.02
in general payments reported to CMS, 2019-2025
41 companies · $2,695 in 2025
The $2,695 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48K · 2020: $7,826 · 2021: $860 · 2022: $1,149 · 2023: $1,717 · 2024: $5,028 · 2025: $2,695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,085 · Consulting Fee: $2,300 · Travel and Lodging: $37.52 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,085.03 |
| Consulting Fee | $2,300.00 |
| Travel and Lodging | $37.52 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $52,457.88 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $3,534.80 | 2019-2025 | Opsumit, Uptravi |
| United Therapeutics Corporation | $2,852.65 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
| Novartis Pharmaceuticals Corporation | $1,115.18 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,035.22 | 2021-2025 | Verquvo, Winrevair |
| Pfizer INC. | $991.80 | 2019-2025 | |
| Amgen INC. | $774.00 | 2019-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $729.96 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $646.67 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $521.95 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $350.44 | 2019-2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $336.18 | 2019-2024 | Avvigo Guidance System |
| Astrazeneca Pharmaceuticals LP | $187.20 | 2019-2023 | Brilinta |
| Medtronic, INC. | $162.97 | 2024 | Symplicity G3 |
| Zoll Respicardia, INC. | $157.51 | 2019 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $149.36 | 2024 | Indigo System |
| Esperion Therapeutics, INC. | $129.28 | 2023-2025 | Nexletol |
| Novo Nordisk INC | $123.34 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $117.58 | 2023-2025 | Lifevest |
| Asahi Intecc USA, INC. | $111.63 | 2020 | |
| Agepha Pharma Fz LLC | $100.23 | 2024 | Lodoco |
| Dentsply Sirona INC | $100.00 | 2023 | Primescan Connect |
| Abbott Laboratories | $92.00 | 2025 | Xience Skypoint |
| Edwards Lifesciences Corporation | $57.24 | 2019-2025 | Pascal |
| Sanofi-Aventis U.S. LLC | $52.71 | 2022-2024 | |
| Cvrx, INC. | $50.43 | 2022 | |
| Lundbeck LLC | $45.36 | 2019 | |
| Medtronic Vascular, INC. | $34.99 | 2019 | |
| Abiomed | $33.20 | 2022 | |
| Gilead Sciences, INC. | $32.61 | 2019 | |
| Recor Medical INC | $32.19 | 2025 | Paradise Ultrasound Renal Denervation System |
| Alnylam Pharmaceuticals INC. | $27.41 | 2025 | Amvuttra |
| Glaxosmithkline, LLC. | $27.16 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $25.90 | 2021 | |
| Inspire Medical Systems, INC. | $25.24 | 2025 | Inspire |
| Kiniksa Pharmaceuticals International, Plc | $22.39 | 2024 | Arcalyst |
| Sandoz INC. | $22.10 | 2023 | Treprostinil |
| Regeneron Healthcare Solutions, INC. | $21.77 | 2019 | |
| Bridgebio Pharma, INC. | $21.56 | 2025 | Attruby |
| Arbor Pharmaceuticals, INC. | $18.24 | 2019 | |
| Chiesi USA, INC. | $14.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhaval Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.